D-884-2013 Class II Terminated

Recalled by Dr. Reddy's Laboratories, Inc. — Bridgewater, NJ

FDA drug recall D-884-2013 was initiated by Dr. Reddy's Laboratories, Inc. on Aug 2, 2013 and is designated Class II. Reason for recall: Microbial Contamination of Non-Sterile Products: A lot of raw material used in the manufacture of Ranitidine was positive for Pseudomonas sp. The recall status is terminated (terminated Mar 19, 2014).

Recall details

Product Type
Drugs
Report Date
Aug 21, 2013
Initiation Date
Aug 2, 2013
Termination Date
Mar 19, 2014
Voluntary/Mandated
Voluntary: Firm initiated

Product description

Ranitidine Hydrochloride Tablets, USP, 150 mg, OTC, a) Equate brand Maximum Strength Acid Reducer, 65 count bottle Dist. By: Wal-Mart Stores, Inc., Bentonville, AR 72710, NDC 49035-404-61 b)Equaline brand maximum strength heartburn relief, , DISTRIBUTED BY SUPERVALU INC., EDEN PRAIRIE, MN 55344, NDC 41163-404-61, c)Wal-Zan brand 150, MAXIMUM STRENGTH, 24 count bottlle, DISTRIBUTED BY: WALGREEN CO., 200 WILMOT RD., DEERFIELD, IL 63015, NDC 0363-0404-34

Reason for recall

Microbial Contamination of Non-Sterile Products: A lot of raw material used in the manufacture of Ranitidine was positive for Pseudomonas sp.

Distribution pattern

Nationwide

Code information

a)Lot: 5055822, exp. 03/13; 5056317, exp. 03/15; and 5056507, exp. 04/15 b)Lot: 7956571C, exp. 04/15 c)Lot: 7956572A, exp. 04/15

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-884-2013
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-884-2013. Report a data issue: hello@regdatalab.com.